LantheusLNTH
About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Employees: 808
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $55M | Put options by funds: $37.3M
10% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 168
6.58% more ownership
Funds ownership: 100.72% [Q3] → 107.3% (+6.58%) [Q4]
5% less first-time investments, than exits
New positions opened: 71 | Existing positions closed: 75
3% less funds holding
Funds holding: 493 [Q3] → 478 (-15) [Q4]
13% less capital invested
Capital invested by funds: $7.65B [Q3] → $6.68B (-$976M) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 8 (-2) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
B. Riley Securities Justin Walsh 20% 1-year accuracy 2 / 10 met price target | 20%upside $122 | Buy Maintained | 21 Mar 2025 |
Truist Securities Richard Newitter 54% 1-year accuracy 26 / 48 met price target | 25%upside $127 | Buy Maintained | 27 Feb 2025 |
Financial journalist opinion









